This article from Bain & Company, "How to Successfully Scale Generative AI in Pharma," outlines the critical shift pharmaceutical companies must make from isolated generative AI experiments to a comprehensive, enterprise-wide strategy.
It highlights that a significant portion of pharma executives are already incorporating expected savings from generative AI into their budgets and actively developing use cases, moving beyond mere ideation.
The article stresses that true leaders will distinguish themselves by scaling winning applications across their operations, driven by a strategic operating model that prioritises high-value opportunities.
To achieve this, companies need a three-pronged approach: defining their strategic posture for decision-making and funding, leading through change with strong internal champions, and building foundational support through talent acquisition, strategic partnerships, and a robust ethical and regulatory framework.